# 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

> **NCT02359500** · PHASE1 · TERMINATED · sponsor: **Lale Kostakoglu** · enrollment: 71 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Carcinoid Tumors

## Interventions

- **DRUG:** 68Ga-DOTATOC PET

## Key facts

- **NCT ID:** NCT02359500
- **Lead sponsor:** Lale Kostakoglu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2017-01-23
- **Final completion:** 2017-01-23
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** compound no longer available
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02359500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02359500, "68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02359500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*